Literature DB >> 24648510

Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Stephanie A Planque1, Yasuhiro Nishiyama, Mariko Hara, Sari Sonoda, Sarah K Murphy, Kenji Watanabe, Yukie Mitsuda, Eric L Brown, Richard J Massey, Stanley R Primmer, Brian O'Nuallain, Sudhir Paul.   

Abstract

Peptide bond-hydrolyzing catalytic antibodies (catabodies) could degrade toxic proteins, but acquired immunity principles have not provided evidence for beneficial catabodies. Transthyretin (TTR) forms misfolded β-sheet aggregates responsible for age-associated amyloidosis. We describe nucleophilic catabodies from healthy humans without amyloidosis that degraded misfolded TTR (misTTR) without reactivity to the physiological tetrameric TTR (phyTTR). IgM class B cell receptors specifically recognized the electrophilic analog of misTTR but not phyTTR. IgM but not IgG class antibodies hydrolyzed the particulate and soluble misTTR species. No misTTR-IgM binding was detected. The IgMs accounted for essentially all of the misTTR hydrolytic activity of unfractionated human serum. The IgMs did not degrade non-amyloidogenic, non-superantigenic proteins. Individual monoclonal IgMs (mIgMs) expressed variable misTTR hydrolytic rates and differing oligoreactivity directed to amyloid β peptide and microbial superantigen proteins. A subset of the mIgMs was monoreactive for misTTR. Excess misTTR was dissolved by a hydrolytic mIgM. The studies reveal a novel antibody property, the innate ability of IgMs to selectively degrade and dissolve toxic misTTR species as a first line immune function.

Entities:  

Keywords:  Aging; Amyloid; Amyloidosis; Antibodies; Catalytic Antibody; Innate Immunity; Protein Evolution; Superantigen; Transthyretin

Mesh:

Substances:

Year:  2014        PMID: 24648510      PMCID: PMC4036335          DOI: 10.1074/jbc.M114.557231

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  98 in total

Review 1.  Intravenous immunoglobulin: exploiting the potential of natural antibodies.

Authors:  Srini V Kaveri
Journal:  Autoimmun Rev       Date:  2012-02-12       Impact factor: 9.754

2.  Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy.

Authors:  Pedro Filipe Teixeira; Filipe Cerca; Sofia D Santos; Maria João Saraiva
Journal:  J Biol Chem       Date:  2006-06-02       Impact factor: 5.157

3.  Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells.

Authors:  Fabian Köhler; Eva Hug; Cathrin Eschbach; Sonja Meixlsperger; Elias Hobeika; Juliane Kofer; Hedda Wardemann; Hassan Jumaa
Journal:  Immunity       Date:  2008-12-11       Impact factor: 31.745

Review 4.  Superantibody activities: new players in innate and adaptive immune responses.

Authors:  H Kohler; S Paul
Journal:  Immunol Today       Date:  1998-05

5.  Site-directed mutagenesis of proteolytic antibody light chain.

Authors:  Q S Gao; M Sun; A R Rees; S Paul
Journal:  J Mol Biol       Date:  1995-11-10       Impact factor: 5.469

6.  Intra- and extravascular distribution of albumin and immunoglobulin in man.

Authors:  N Rossing
Journal:  Lymphology       Date:  1978-12       Impact factor: 1.286

7.  Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies.

Authors:  Yukie Mitsuda; Stephanie Planque; Mariko Hara; Robert Kyle; Hiroaki Taguchi; Yasuhiro Nishiyama; Sudhir Paul
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

8.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

9.  Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.

Authors:  Per Westermark; Joakim Bergström; Alan Solomon; Charles Murphy; Knut Sletten
Journal:  Amyloid       Date:  2003-08       Impact factor: 7.141

Review 10.  Amyloidosis.

Authors:  Mark B Pepys
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

View more
  18 in total

1.  Specific amyloid β clearance by a catalytic antibody construct.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Sari Sonoda; Yan Lin; Hiroaki Taguchi; Mariko Hara; Steven Kolodziej; Yukie Mitsuda; Veronica Gonzalez; Hameetha B R Sait; Ken-ichiro Fukuchi; Richard J Massey; Robert P Friedland; Brian O'Nuallain; Einar M Sigurdsson; Sudhir Paul
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 2.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

3.  Catalytic antibodies in patients with systemic lupus erythematosus.

Authors:  Vandana Pradhan; Pallavi Pandit; Prathamesh Surve; Maxime Lecerf; Anjali Rajadhyaksha; Milind Nadkar; Prasad V Khadilkar; Durga A Chougule; Aalaap A Naigaonkar; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Kanjaksha Ghosh; Srini V Kaveri
Journal:  Eur J Rheumatol       Date:  2018-08-07

4.  Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.

Authors:  Jeffrey N Higaki; Avi Chakrabartty; Natalie J Galant; Kevin C Hadley; Bradley Hammerson; Tarlochan Nijjar; Ronald Torres; Jose R Tapia; Joshua Salmans; Robin Barbour; Stephen J Tam; Ken Flanagan; Wagner Zago; Gene G Kinney
Journal:  Amyloid       Date:  2016-03-16       Impact factor: 7.141

5.  Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia.

Authors:  Evgeny A Ermakov; Ludmila P Smirnova; Nikolay A Bokhan; Arkadiy V Semke; Svetlana A Ivanova; Valentina N Buneva; Georgy A Nevinsky
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Extreme Diversity of IgGs Against Histones, DNA, and Myelin Basic Protein in the Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis.

Authors:  Irina A Kostrikina; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  Biomolecules       Date:  2020-04-18

7.  IgG Conformer's Binding to Amyloidogenic Aggregates.

Authors:  Monichan Phay; Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Veronika Blinder; Tiernan T O'Malley; Alan Solomon; Dominic M Walsh; Brian O'Nuallain
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

8.  DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia.

Authors:  Evgeny A Ermakov; Ludmila P Smirnova; Taisiya A Parkhomenko; Pavel S Dmitrenok; Nina M Krotenko; Nikolai S Fattakhov; Nikolay A Bokhan; Arkadiy V Semke; Svetlana A Ivanova; Valentina N Buneva; Georgy A Nevinsky
Journal:  Open Biol       Date:  2015-09       Impact factor: 6.411

9.  Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24.

Authors:  Sarah M Gunter; Kathryn M Jones; Bin Zhan; Heather T Essigmann; Kristy O Murray; Melissa N Garcia; Rodion Gorchakov; Maria Elena Bottazzi; Peter J Hotez; Eric L Brown
Journal:  Am J Trop Med Hyg       Date:  2015-11-23       Impact factor: 2.345

10.  Substrate specificity of healthy human sera IgG antibodies with peroxidase and oxydoreductase activities.

Authors:  Anna S Tolmacheva; Evgeny A Ermakov; Valentina N Buneva; Georgy A Nevinsky
Journal:  R Soc Open Sci       Date:  2018-01-31       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.